FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileGeron Corporation
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
GERN
Geron Corporation Stock AnalysisComprehensive stock analysis for Geron Corporation (GERN) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisGERN
GERN
Geron Corporation
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
GERN
  1. Home
  2. Stocks
  3. Geron Corporation

Geron Corporation

🇺🇸GERN•NASDAQ

Geron Corporation

🇺🇸GERN•NASDAQ
Market cap
$622.98M
Sentiment

Your view on GERN

Mkt Cap
$622.98M
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Geron Corporation

Industry
Biotechnology
Sector
Healthcare
CEO
Harout Semerjian
Headquarters
919 East Hillsdale Boulevard, Foster City, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Harout Semerjian
Headquarters
919 East Hillsdale Boulevard, Foster City, CA, US
Description

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies.

It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

The company was incorporated in 1990 and is headquartered in Foster City, California.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Geron Corporation from FRC's valuation model, read against the market price. GERN last traded at $0.97; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Geron Corporation. Starting points for Geron Corporation: EPS -$0.07, beta 0.61 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Geron Corporation. Geron Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Geron Corporation. Trailing twelve-month EPS for Geron Corporation stands at -$0.07. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 16, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$5.89

average of analysts' targets

 

$5.89

Low $4.00

Median $6.00

High $8.00

 

Analyst Ratings

Buy22 ratings
  • Strong Buy0
  • Buy15
  • Hold7
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$0.00$0.01-$0.03$0.07
Low estimate-$0.00$0.01-$0.06$0.03
High estimate$0.01$0.01-$0.01$0.14
No. of analysts2123
Year-ago EPS-$0.03-$0.01-$0.13—
Growth+112.5%+187.7%+78.5%—

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$65.50M$68.99M$235.32M$320.51M
Low estimate$64.92M$67.08M$234.67M$318.67M
High estimate$66.07M$72.14M$235.98M$322.33M
No. of analysts3244
Year-ago revenue$48.02M$51.84M$183.88M—
Growth+36.4%+33.1%+28.0%—
Recent analyst actions15 rating and price-target changes, latest Oct 29, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga; as of Nov 16, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Geron Corporation. Geron Corporation has reported as a listed company since 1996. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold GERN19 companies · 8 funds
Compare GERN with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ATNMActinium Pharmaceuticals, Inc.Biotechnology$52M
  • COAGHemab Therapeutics Holdings, Inc. Common StockBiotechnology$1.9B
  • DMRADamora Therapeutics, Inc.Biotechnology$1.3B
  • INCYIncyte CorporationBiotechnology$24.7B
  • IPSCCentury Therapeutics, Inc.Biotechnology$299M
  • RIGLRigel Pharmaceuticals, Inc.Biotechnology$837M
  • SLSSELLAS Life Sciences Group, Inc.Biotechnology$1.6B

More Biotechnology companies

  • SLXNWSilexion Therapeutics Ltd.NASDAQ$70,256
  • SMMTSummit Therapeutics Inc.NASDAQ$11.3B
  • SNANFSona Nanotech Inc.OTC$36M
  • SNBIFSanBio Company LimitedOTC$1.3B
  • SNDXSyndax Pharmaceuticals, Inc.NASDAQ$851M
  • SNGXSoligenix, Inc.NASDAQ$8M
  • SNNAQSienna Biopharmaceuticals, Inc.OTC$3,091
  • SNTISenti Biosciences, Inc.NASDAQ$4M
  • SOLTFNxera Pharma Co., Ltd.OTC$492M
  • SONA.CNSona Nanotech Inc.CNQ$49M
  • SPHDFSanthera Pharmaceuticals Holding AGOTC$295M
  • SPHRFStarpharma Holdings LimitedOTC$134M

ETFs holding Geron Corporation

% of the fund

  • XBIState Street SPDR S&P Biotech ETF$10.0B in assets0.18%
  • VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
  • IWMiShares Russell 2000 ETF$76.6B in assets0.02%
  • VXFVanguard Extended Market ETF$30.2B in assets0.01%
  • BBPVirtus LifeSci Biotech Products ETF$133M in assets1.14%
  • SBIOALPS Medical Breakthroughs ETF$187M in assets0.41%
  • VTWGVanguard Russell 2000 Growth ETF$1.4B in assets0.03%
  • PRFZInvesco RAFI US 1500 Small-Mid ETF$2.6B in assets0.03%

Largest holders first, then the funds most concentrated in GERN.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Geron Corporation, and how their positions are changing. At a $623.0M market value, institutional positions materially move Geron Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Geron Corporation executives and directors. Shares of Geron Corporation have traded between $1.04 and $4.21 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Geron Corporation. Coverage tracks Geron Corporation within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Geron Corporation.

GERN Analysis
Fair
Past4
Growth5
Health3
Profit1
Value1

News

Latest Market News